8-K
3D Systems Corp (DDD)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_________________
FORM 8-K
_________________
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 27, 2023
_______________________________
3D SYSTEMS CORPORATION
(Exact name of registrant as specified in its charter)
_______________________________
| Delaware | 001-34220 | 95-4431352 |
|---|---|---|
| (State or Other Jurisdiction of Incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) |
333 Three D Systems Circle
Rock Hill, South Carolina 29730
(Address of Principal Executive Offices) (Zip Code)
(803) 326-3900
(Registrant's telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
_______________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|---|---|
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
|---|---|---|
| Common stock, par value $0.001 per share | DDD | New York Stock Exchange |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02. Results of Operations and Financial Condition. On February 28, 2022, 3D Systems Corporation (the “Company”) issued a press release announcing the Company’s unaudited results of operations for the fourth quarter and year ended December 31, 2022 (the “Press Release”). A copy of the Press Release is furnished herewith as Exhibit 99.1 and is incorporated into this Item 2.02 by reference. The information in this Item 2.02 (and in the Press Release) shall not be deemed “filed” with the Securities and Exchange Commission (the “SEC”) for purposes of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor incorporated by reference in any registration statement filed by the Company under the Securities Act of 1933, as amended (the “Securities Act”).
Item 7.01. Regulation FD Disclosure.
Included in the Press Release is the Company’s announcement of a delay of the release of its audited financial results for the fourth quarter and year ended December 31, 2022 and the filing of its Annual Report on Form 10-K for the fiscal year ended December 31, 2022. Also included in the Press Release is an announcement that the Company plans to hold a conference call and webcast at 8:30 a.m., Eastern Time, on Wednesday, March 1, 2023, to discuss its anticipated fourth quarter and year ended December 31, 2022 financial results and other matters relating to the Company’s plans and operations. A copy of the Press Release, which contains additional information regarding how to access the conference call and webcast and how to listen to a recorded playback of the call after it is completed, is furnished herewith as Exhibit 99.1 and is incorporated into this Item 7.01 by reference. The slides to be presented on the webcast are furnished herewith as Exhibit 99.2 and incorporated into this Item 7.01 by reference.
The information in this Item 7.01 (and in the Press Release and slides) shall not be deemed “filed” with the SEC for purposes of the Exchange Act, nor incorporated by reference in any registration statement filed by the Company under the Securities Act.
Item 8.01. Other Events.
On February 27, 2023, the Company entered into individual settlement agreements with the U.S. Departments of State (“DDTC”) and Commerce (“BIS”) resolving previously disclosed potential violations of U.S. export control laws, including with regard to Quickparts.com, Inc., a former subsidiary of the Company. The Company also settled claims by the Civil Division of the Department of Justice (“DOJ”) of alleged related violations of the False Claims Act. For more information regarding these previously disclosed possible violations, see “Export Controls and Government Contracts Compliance Matter” in Note 14 – Commitments and Contingencies to the Financial Statements in Part I, Item 1 of the Company’s Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2022, filed with the SEC on November 9, 2022.
As part of these settlement agreements, the Company has agreed to pay $15,047,784.54 in civil monetary penalties to these agencies, and agreed to spend $10,000,000 on remedial compliance measures over the next three years. DDTC and BIS are further imposing remedial compliance measures in their agreements, including the appointment of a Special Compliance Officer to monitor the Company’s export compliance, external audit requirements, and additional processes, procedures, and training related to export control compliance. The agencies are not criminally prosecuting the Company, and the Company is not subject to any administrative debarment.
By settling these matters, the Company has closed all potential violations of export controls that the Company had previously disclosed to DDTC, BIS, as well as the alleged violations of the False Claims Act by the DOJ. The Company has already made meaningful improvements to its compliance program and will continue to further enhance its export compliance going forward. The Company has fully reserved for the civil monetary penalties and will expense the remedial compliance measures over the next three years as incurred.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
| 99.1 | Press Release issued by 3D Systems Corporation, dated February 28, 2023. |
|---|---|
| 99.2 | Investor information to be presented by 3D Systems Corporation on March 1, 2023. |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| 3D SYSTEMS CORPORATION | ||
|---|---|---|
| Date: March 1, 2023 | By: | /s/ Michael Turner |
| Michael Turner | ||
| Executive Vice President and Chief Finance Officer |
EdgarFiling EXHIBIT 99.1
3D Systems Reports Fourth Quarter and Full Year 2022 Financial Results
ROCK HILL, S.C., Feb. 28, 2023 (GLOBE NEWSWIRE) -- 3D Systems Corporation (NYSE:DDD) announced today its financial results for the fourth quarter and full year ended December 31, 2022.
Fourth Quarter Financial Results and Recent Business Highlights
(All numbers are unaudited and are presented in thousands, except per share amounts or otherwise noted)
- Q4 2022 revenue of $132,732 decreased 12.0% compared to Q4 2021; Non-GAAP Q4 2022 revenue on a constant currency basis^(1)^ decreased 7.6%, reflecting weakness in the dental orthodontics market
- Net loss of $25,553, diluted loss per share of $0.20, and diluted non-GAAP loss per share of $0.06 ^(1)^
- Negative adjusted EBITDA^(1)^ of $4,808 reflects inflationary impacts on our input costs, unfavorable product mix, and continued investments in growth areas of our business and product portfolio
Full Year 2022 Financial Highlights
- 2022 revenue of $538,031 decreased 12.6% compared to 2021 revenue of $615,639; Non-GAAP revenue adjusted for divestitures and on a constant currency^(1)^ basis increased 3.3%, reflecting solid demand in both the Industrial and Healthcare segments despite macroeconomic challenges, offset by lower sales to certain dental market customers
- Net loss of $122,711, diluted loss per share of $0.96, and diluted non-GAAP loss per share of $0.23^(1)^
- Negative adjusted EBITDA^(1)^ of $5,781 reflects inflationary impacts on our input costs and continued investments in growth areas of our business and product portfolio
- Cash and short-term investments of $568,737 position the company for continued growth investments
2023 Outlook
- Continued softness in dental orthodontic market fully offset by strong performance in Industrial and non-dental Healthcare Solutions markets leading to mid-single digit revenue growth
- Positive full year Adjusted EBITDA and free cash flow support an already-strong balance sheet
- Sustained investments in core technologies and emerging regenerative medicine markets
| (in thousands, expect per share data) | Quarter Ended December 31, | Year EndedDecember 31, | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue Growth Rates (%) as reported | (12.0 | )% | (12.6 | )% | ||||||||
| Non-GAAP Revenue Growth Rates (%) excluding divestitures | (12.0 | )% | (1.1 | )% | ||||||||
| Non-GAAP Revenue Growth Rates (%) excluding divestitures and FX effects | (7.6 | )% | 3.3 | % | ||||||||
| Quarter Ended December 31, | Year Ended December 31, | |||||||||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| (in thousands, expect per share data) | 2022 | 2021 | 2022 | 2021 | ||||||||
| Revenue | $ | 132,732 | $ | 150,870 | $ | 538,031 | $ | 615,639 | ||||
| Operating (loss) | $ | (28,044 | ) | $ | (3,842 | ) | $ | (117,019 | ) | $ | (33,069 | ) |
| Net (loss) income | $ | (25,553 | ) | $ | (6,200 | ) | $ | (122,711 | ) | $ | 322,052 | |
| Basic income (loss) per share | $ | (0.20 | ) | $ | (0.05 | ) | $ | (0.96 | ) | $ | 2.62 | |
| Diluted income (loss) per share | $ | (0.20 | ) | $ | (0.05 | ) | $ | (0.96 | ) | $ | 2.55 | |
| Quarter Ended December 31, | Year Ended December 31, | |||||||||||
| (in thousands, expect per share data) | 2022 | 2021 | 2022 | 2021 | ||||||||
| Non-GAAP measures for year-over-year comparisons ^(1)^ | ||||||||||||
| Non-GAAP Revenue | $ | 132,732 | $ | 150,870 | $ | 538,031 | $ | 543,967 | ||||
| Non-GAAP operating (loss) income | $ | (9,912 | ) | $ | 12,359 | $ | (26,877 | ) | $ | 33,529 | ||
| Non-GAAP net (loss) income | $ | (7,474 | ) | $ | 11,570 | $ | (29,383 | ) | $ | 41,473 | ||
| Non-GAAP basic income (loss) per share | $ | (0.06 | ) | $ | 0.09 | $ | (0.23 | ) | $ | 0.34 | ||
| Non-GAAP diluted income (loss) per share | $ | (0.06 | ) | $ | 0.09 | $ | (0.23 | ) | $ | 0.33 | ||
| Adjusted EBITDA | $ | (4,808 | ) | $ | 17,929 | $ | (5,781 | ) | $ | 56,151 |
^(1)^ See “Presentation of Information in this Press Release” below for a description and the Appendix for reconciliation of non-GAAP revenue, adjusted for divestitures, operating income (loss), net income (loss) and basic and diluted income (loss) per share to the most closely comparable GAAP measure.
Summary Comments on Results
Commenting on 2022 results and the outlook for 2023, Dr. Jeffrey Graves, President and CEO of 3D Systems said, "2022 was a year of strong investment in our development of next generation hardware, materials, and software platforms despite facing significant macroeconomic and geopolitical headwinds as well as softness in our key dental orthodontic market attributable to inflationary pressure on consumer discretionary spending. By sustaining this investment focus, we made major progress on the refresh of our printer portfolio, as evidenced in part by recent new product announcements. More such announcements will follow throughout 2023 as we complete the refresh of virtually our entire product portfolio. This organic development was complemented by our acquisition of three early-stage technology platforms over the last 18 months, which further broadened the range of customer applications we can now address. Continuity in these initiatives was essential given the continued momentum we are seeing in the adoption of additive manufacturing in production environments across both our Healthcare and Industrial Solutions markets. Sustaining these investments in the face of 2022's many headwinds required us to target our investment spending carefully, control operating costs, and leverage our strong balance sheet. This focus, combined with our improved operational execution gained through selective in-sourcing of manufacturing, has reinforced our industry-leading breadth of additive manufacturing technologies, our unparalleled applications expertise, and scale needed to meet our expanding customer needs for years to come."
"For 2023, given the continued inflationary environment and the pressure it inevitably puts on consumer discretionary spending, our revenue guidance assumes continued softness in the dental orthodontic market. On a positive note, we expect this softness in dental to be more than offset by the strong growth we currently anticipate in virtually all other key markets across our Healthcare and Industrial Solutions segments. This strength is being driven by a rapid expansion of new production applications and the accelerating efforts by our global customers to restructure their supply chains and reduce enterprise risk. The net result of these effects is an expected consolidated 2023 revenue growth rate in the mid-single digits, with mid-teens growth across all our non-dental markets."
"In 2023 we will place a high priority on profitability and cash performance as we increasingly harvest the gains in efficiency that our operations in-sourcing has provided. This focus will enable us to offset headwinds in our dental orthodontic market and to support our increasing investment in Systemic Bio and other regenerative medicine initiatives. From these investments, we expect to make meaningful announcements in these areas over the next 12 to 24 months as we move through pre-clinical trials for our biological applications and customer acceptance tests in the pharmaceutical markets. To further our gains in operating efficiency, this morning we announced a multi-pronged restructuring initiative designed to realize additional cost synergies in multiple parts of our business. We will complete these actions in the first half of this year. Based on our projected growth profile, combined with the cost actions completed last year and in early 2023, we expect to generate positive Adjusted EBITDA and positive free cash flow for full year 2023, excluding one-time restructuring costs."
"By executing on our strategic plan, we have positioned our Healthcare and Industrial Solutions segments for strong financial performance against the backdrop of an additive manufacturing industry that is poised for rapid future growth. In addition to this exciting trajectory for our current core business, we increasingly understand the remarkable potential of our long-term partnership with United Therapeutics to manufacture human organs for transplantation, and the growth benefits we expect from Systemic Bio, our early-stage business whose unique 3D printed organ-on-a-chip technology has the potential to revolutionize drug development in the pharmaceutical industry."
Dr. Graves concluded, "In designing our budget for 2023, we believe our investment strategy represents the best balance between short term profitability and sustained revenue growth in the current economic and geopolitical environment that we are experiencing. By delivering positive Adjusted EBITDA and free cash generation this year, which will further enhance our already strong balance sheet, while making the most critical investments in R&D and corporate infrastructure required to meet rapidly expanding adoption of additive manufacturing across our Industrial, Healthcare, and emerging biological markets, we believe we are well positioned to deliver sustained value creation to our customers and shareholders in 2023 and the years to follow."
Summary of Fourth Quarter Results
Revenue for the fourth quarter of 2022 decreased 12.0% to $132,732 compared to the same period last year, and non-GAAP revenue on a constant currency basis decreased 7.6%. The decline of non-GAAP revenue on a constant currency basis primarily reflects lower sales to certain dental market customers due to macroeconomic factors that are negatively impacting the demand for elective dental procedures, partially offset by continued solid product and service demand across other areas of the business.
Industrial Solutions revenue decreased 5.7% to $72,038 compared to the same period last year, however non-GAAP revenue on a constant currency basis increased 1.1% year over year. Healthcare Solutions revenue decreased 18.5% to $60,694 and non-GAAP revenue on a constant currency basis decreased 16.6% year over year.
Gross profit margin in the fourth quarter of 2022 was 41.2% compared to 43.9% in the same period last year. Non-GAAP gross profit margin was 40.9% compared to 44.1% in the same period last year. Gross profit margin decreased primarily due to input cost inflation and unfavorable product mix.
Operating expenses increased 18.0% to $82,674 in the fourth quarter of 2022 compared to the same period a year ago. On a non-GAAP basis, operating expenses were $64,144, an 18.2% increase from the same period a year ago. The increase in non-GAAP operating expenses primarily reflects spending in targeted areas to support future growth, including expenses from acquired businesses, research and development, and investments in corporate infrastructure.
Summary of Full-Year 2022 Results
Revenue for 2022 of $538,031 decreased 12.6% compared to the prior year. Non-GAAP revenue adjusted for divestitures and on a constant currency basis increased 3.3%. The increase in non-GAAP revenue reflects solid demand in both the Industrial and Healthcare Solutions segments despite macroeconomic challenges, offset by lower sales to certain dental market customers.
Industrial Solutions revenue decreased 10.5% to $277,043 compared to the prior year, and non-GAAP revenue adjusted for divestitures and on a constant currency basis increased 9.7%. Healthcare Solutions revenue decreased 14.8% to $260,988, and non-GAAP revenue adjusted for divestitures and on a constant currency basis decreased 2.9%.
Gross profit margin for the full year 2022 was 39.8% compared to 42.8% in the prior year. Non-GAAP gross profit margin was 39.8% for the full year 2022 compared to 42.5% in the prior year. Gross profit margin decreased primarily due to input cost inflation and unfavorable product mix.
Operating expenses for the full year 2022 increased 11.6% to $331,252 compared to the prior year. The higher operating expenses reflect spending in targeted areas to support future growth, including expenses from acquired businesses, research and development, and investments in corporate infrastructure, as well as a $19,888 increase in legal and other settlement costs, partially offset by the absence of expenses from divested businesses. Non-GAAP operating expenses were $241,124 in 2022, a 22.1% increase from the prior year. The higher non-GAAP operating expenses primarily reflect spending to support future growth.
2023 Outlook
The company is providing full-year 2023 financial guidance as follows:
| Revenue: | $545 - $575 million |
|---|---|
| Non-GAAP Gross Profit Margin: | 40% - 42% |
| Adjusted EBITDA: | Break even or better |
| Free Cash Flow: | Break even or better |
For purposes of the above guidance, Free Cash Flow is defined as Adjusted EBITDA less changes in working capital less capital expenditures.
Financial Liquidity
At December 31, 2022, the company had cash and cash equivalents and short-term investments of $568,737, a decrease of $220,920 since December 31, 2021. The decrease resulted primarily from cash paid for acquisitions and other investments of $103,647, cash used in operations of $68,395, capital expenditures of $22,499, and taxes paid related to net share settlement of equity awards $10,864. At December 31, 2022, the company had total debt net of deferred financing costs of $449,510.
Subsequent Events
Yesterday, the company resolved its ongoing export controls investigations with the U.S. Department of State, the U.S. Department of Commerce, and the U.S. Department of Justice. The company entered into individual settlement agreements which resulted in civil monetary penalties as well as certain remedial compliance measures to be completed as part of a three year consent agreement.
Q4 and FY 2022 Conference Call and Webcast
3D Systems will delay the filing of its Annual Report on Form 10-K for the fiscal year ended December 31, 2022 and file a Form 12b-25, Notification of Late Filing, with the Securities and Exchange Commission, which extends the deadline to file the Form 10-K. The delay in filing is primarily due to additional time required by the Company to complete its financial reporting close procedures. As a result, the Company's independent registered public accounting firm has not yet completed its audits of the Company's financial statements as of December 31, 2022. It has no impact on the company's operations or on its ability to discuss its 2022 results and 2023 outlook.
The company will host a conference call and simultaneous webcast to discuss these results on March 1, 2023, which may be accessed as follows:
Date: Wednesday, March 1, 2023 Time: 8:30 a.m. Eastern Time Listen via webcast: www.3dsystems.com/investor Participate via telephone: 201-689-8345
A replay of the webcast will be available approximately two hours after the live presentation at www.3dsystems.com/investor.
Forward-Looking Statements
Certain statements made in this release that are not statements of historical or current facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to be materially different from historical results or from any future results or projections expressed or implied by such forward-looking statements. In many cases, forward looking statements can be identified by terms such as “believes,” “belief,” “expects,” “may,” “will,” “estimates,” “intends,” “anticipates” or “plans” or the negative of these terms or other comparable terminology. Forward-looking statements are based upon management’s beliefs, assumptions and current expectations and may include comments as to the company’s beliefs and expectations as to future events and trends affecting its business and are necessarily subject to uncertainties, many of which are outside the control of the company. The factors described under the headings “Forward-Looking Statements” and “Risk Factors” in the company’s periodic filings with the Securities and Exchange Commission, as well as other factors, could cause actual results to differ materially from those reflected or predicted in forward-looking statements. Although management believes that the expectations reflected in the forward-looking statements are reasonable, forward-looking statements are not, and should not be relied upon as a guarantee of future performance or results, nor will they necessarily prove to be accurate indications of the times at which such performance or results will be achieved. The forward-looking statements included are made only as the date of the statement. 3D Systems undertakes no obligation to update or revise any forward-looking statements made by management or on its behalf, whether as a result of future developments, subsequent events or circumstances or otherwise, except as required by law.
Presentation of Information in this Press Release
3D Systems reports its financial results in accordance with GAAP. Management also reviews and reports certain non-GAAP measures, including: non-GAAP revenue, non-GAAP Gross profit, non-GAAP Gross profit margin, non-GAAP Operating expenses, non-GAAP Operating (loss)/income, non-GAAP Interest and other income/(expense), net, non-GAAP Net income (loss), non-GAAP Basic and Diluted Income (Loss) per Share, adjusted EBITDA and adjusted EBITDA Margin. These non-GAAP measures exclude certain special items that management does not view as part of 3D Systems’ underlying results as they may be highly variable, may be unusual or infrequent, are difficult to predict and can distort underlying business trends and results. Management believes that the non-GAAP measures provide useful additional insight into underlying business trends and results and provide a more meaningful comparison of period-over-period results. Additionally, management uses the non-GAAP measures for planning, forecasting and evaluating business and financial performance, including allocating resources and evaluating results relative to employee compensation targets. 3D Systems’ non-GAAP measures are not calculated in accordance with or as required by GAAP and may not be calculated the same as similarly titled measures used by other companies. These non-GAAP measures should thus be considered as supplemental in nature and not considered in isolation or as a substitute for the related financial information prepared in accordance with GAAP.
To calculate the non-GAAP measures, 3D Systems excludes the impact of the following items:
- amortization of intangible assets, a non-cash expense, as 3D Systems’ intangible assets were primarily acquired in connection with business combinations;
- costs incurred in connection with acquisitions and divestitures, such as legal, consulting and advisory fees;
- stock-based compensation expenses, a non-cash expense;
- restructuring charges (cost optimization plans), impairment charges, including goodwill, divestiture gains or losses, and severance charges pertaining to senior level employees;
- certain compensation expense related to the 2021 Volumetric acquisition; and
- revenue from divestitures included in current and comparable periods necessary to calculate revenue growth excluding the impact of divestitures.
Amortization of intangibles, acquisition and divestiture related costs are excluded from non-GAAP measures as the timing and magnitude of business combination transactions are not predictable, can vary significantly from period to period and the purchase price allocated to amortizable intangible assets and the related amortization period are unique to each acquisition. Amortization of intangible assets will recur in future periods until such intangible assets have been fully amortized. While intangible assets contribute to the Company’s revenue generation, the amortization of intangible assets does not directly relate to the sale of the Company’s products or services. Additionally, intangible asset amortization expense typically fluctuates based on the size and timing of the Company’s acquisition activity. Accordingly, the Company believes excluding the amortization of intangible assets enhances the Company’s and investors’ ability to compare the Company’s past financial performance with its current performance and to analyze underlying business performance and trends. Although stock-based compensation is a key incentive offered to certain of our employees, we continue to evaluate our business performance excluding stock-based compensation; therefore, it is excluded from non-GAAP measures. Stock-based compensation expenses will recur in future periods. Restructuring charges (cost optimization plans), impairment charges, including goodwill, divestiture gains or losses, and severance charges pertaining to senior level employees, are excluded from non-GAAP measures as the frequency and magnitude of these activities may vary widely from period to period. Additionally, impairment charges, including goodwill, are non-cash. Furthermore, 3D Systems excludes contingent consideration recorded as compensation expense related to the 2021 Volumetric acquisition from non-GAAP measures as management evaluates financial performance excluding this expense, which is viewed by management as similar to acquisition consideration.
The matters discussed above are tax effected, as applicable, in calculating non-GAAP net income and basic and diluted earnings per share.
Adjusted EBITDA, defined as net income, plus income tax (provision)/benefit, interest and other income/(expense), net, stock-based compensation expense, amortization of intangibles, depreciation expense and other non-recurring and/or non-cash items all as described above, is used by management to evaluate performance and helps measure financial performance period-over-period.
A reconciliation of GAAP to non-GAAP financial measures is provided in the accompanying schedules.
3D Systems does not provide forward-looking guidance for certain measures on a GAAP basis. The company is unable to provide a quantitative reconciliation of forward-looking non-GAAP gross margins and non-GAAP operating expenses to the most directly comparable forward-looking GAAP measures without unreasonable effort because certain items, including legal, acquisition expenses, stock-compensation expense, intangible amortization expense, restructuring expenses, and goodwill impairment, are difficult to predict and estimate. These items are inherently uncertain and depend on various factors, many of which are beyond the company’s control, and as such, any associated estimate and its impact on GAAP performance could vary materially.
About 3D Systems
More than 30 years ago, 3D Systems brought the innovation of 3D printing to the manufacturing industry. Today, as the leading Additive Manufacturing solutions partner, we bring innovation, performance, and reliability to every interaction - empowering our customers to create products and business models never before possible. Thanks to our unique offering of hardware, software, materials and services, each application-specific solution is powered by the expertise of our application engineers who collaborate with customers to transform how they deliver their products and services. 3D Systems’ solutions address a variety of advanced applications in Healthcare and Industrial Solutions markets such as Medical and Dental, Aerospace & Defense, Automotive and Durable Goods. More information on the company is available at www.3dsystems.com.
| Investor Contact:<br>Media Contact: | investor.relations@3dsystems.com<br>press@3dsystems.com |
|---|
Tables Follow
3D Systems Corporation Unaudited Consolidated Balance Sheets December 31, 2022 and December 31, 2021
| (in thousands, except par value) | December 31, 2021 | ||||
|---|---|---|---|---|---|
| ASSETS | |||||
| Current assets: | |||||
| Cash and cash equivalents | 388,134 | $ | 789,657 | ||
| Short-term investments | 180,603 | — | |||
| Accounts receivable, net of reserves — 3,114 and 2,445 | 93,886 | 106,540 | |||
| Inventories | 137,832 | 92,887 | |||
| Prepaid expenses and other current assets | 33,790 | 42,653 | |||
| Total current assets | 834,245 | 1,031,737 | |||
| Property and equipment, net | 58,072 | 57,257 | |||
| Intangible assets, net | 90,230 | 45,835 | |||
| Goodwill | 385,312 | 345,588 | |||
| Right-of-use assets | 43,655 | 46,356 | |||
| Deferred income tax asset | 7,038 | 5,054 | |||
| Other assets | 28,972 | 17,272 | |||
| Total assets | 1,447,524 | $ | 1,549,099 | ||
| LIABILITIES, REDEEMABLE NON-CONTROLLING INTEREST AND EQUITY | |||||
| Current liabilities: | |||||
| Current lease liabilities | 10,075 | $ | 8,344 | ||
| Accounts payable | 53,826 | 57,366 | |||
| Accrued and other liabilities | 55,571 | 76,994 | |||
| Customer deposits | 6,911 | 7,281 | |||
| Deferred revenue | 26,464 | 28,027 | |||
| Total current liabilities | 152,847 | 178,012 | |||
| Long-term debt, net of deferred financing costs | 449,510 | 446,859 | |||
| Long-term lease liabilities | 41,650 | 47,420 | |||
| Deferred income tax liability | 7,631 | 2,173 | |||
| Other liabilities | 44,180 | 32,254 | |||
| Total liabilities | 695,818 | 706,718 | |||
| Redeemable non-controlling interest | 1,762 | — | |||
| Stockholders’ equity: | |||||
| Common stock, 0.001 par value, authorized 220,000 shares; shares issued 131,207 and 128,375 as of December 31, 2022 and 2021, respectively | 131 | 128 | |||
| Additional paid-in capital | 1,547,597 | 1,501,210 | |||
| Accumulated deficit | (743,962 | ) | (621,251 | ) | |
| Accumulated other comprehensive loss | (53,822 | ) | (37,706 | ) | |
| Total stockholders’ equity | 749,944 | 842,381 | |||
| Total liabilities, redeemable non-controlling interest and stockholders’ equity | 1,447,524 | $ | 1,549,099 |
All values are in US Dollars.
3D Systems Corporation Unaudited Consolidated Statements of Operations Year Ended December 31, 2022 , 2021 and 2020
| Year Ended December 31, | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| (in thousands, except per share amounts) | 2022 | 2021 | 2020 | ||||||
| Revenue: | |||||||||
| Products | $ | 395,396 | $ | 428,742 | $ | 332,799 | |||
| Services | 142,635 | 186,897 | 224,441 | ||||||
| Total revenue | 538,031 | 615,639 | 557,240 | ||||||
| Cost of sales: | |||||||||
| Products | 237,386 | 245,169 | 220,415 | ||||||
| Services | 86,412 | 106,692 | 113,450 | ||||||
| Total cost of sales | 323,798 | 351,861 | 333,865 | ||||||
| Gross profit | 214,233 | 263,778 | 223,375 | ||||||
| Operating expenses: | |||||||||
| Selling, general and administrative | 244,181 | 227,697 | 219,895 | ||||||
| Research and development | 87,071 | 69,150 | 74,143 | ||||||
| Impairment of goodwill | — | — | 48,300 | ||||||
| Total operating expenses | 331,252 | 296,847 | 342,338 | ||||||
| (Loss) income from operations | (117,019 | ) | (33,069 | ) | (118,963 | ) | |||
| Interest and other income (expense), net | (3,790 | ) | 352,609 | (24,447 | ) | ||||
| (Loss) income before income taxes | (120,809 | ) | 319,540 | (143,410 | ) | ||||
| (Provision) benefit for income taxes | (2,140 | ) | 2,512 | (6,184 | ) | ||||
| Net (loss) income before redeemable non-controlling interest | (122,949 | ) | 322,052 | (149,594 | ) | ||||
| Less: net (loss) attributable to redeemable non-controlling interest | (238 | ) | — | — | |||||
| Net (loss) income attributable to 3D Systems Corporation | $ | (122,711 | ) | $ | 322,052 | $ | (149,594 | ) | |
| Net (loss) income per common share | |||||||||
| Basic | $ | (0.96 | ) | $ | 2.62 | $ | (1.27 | ) | |
| Diluted | $ | (0.96 | ) | $ | 2.55 | $ | (1.27 | ) | |
| Weighted average shares outstanding: | |||||||||
| Basic | 127,818 | 122,867 | 117,579 | ||||||
| Diluted | 127,818 | 126,334 | 117,579 |
3D Systems Corporation Unaudited Consolidated Statements of Operations Three Months Ended December 31, 2022 , 2021 and 2020
| Three Months ended December 31, | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| (in thousands, except per share amounts) | 2022 | 2021 | 2020 | ||||||
| Revenue: | |||||||||
| Products | $ | 94,734 | $ | 117,572 | $ | 112,552 | |||
| Services | 37,998 | 33,298 | 60,101 | ||||||
| Total revenue | 132,732 | 150,870 | 172,653 | ||||||
| Cost of sales: | |||||||||
| Products | 55,541 | 64,918 | 72,465 | ||||||
| Services | 22,561 | 19,734 | 27,739 | ||||||
| Total cost of sales | 78,102 | 84,652 | 100,204 | ||||||
| Gross profit | 54,630 | 66,218 | 72,449 | ||||||
| Operating expenses: | |||||||||
| Selling, general and administrative | 58,783 | 50,897 | 52,682 | ||||||
| Research and development | 23,891 | 19,163 | 19,036 | ||||||
| Total operating expenses | 82,674 | 70,060 | 71,718 | ||||||
| Loss from operations | (28,044 | ) | (3,842 | ) | 731 | ||||
| Interest and other (expense) income, net | 1,666 | (1,787 | ) | (16,849 | ) | ||||
| (Loss) income before income taxes | (26,378 | ) | (5,629 | ) | (16,118 | ) | |||
| (Provision) benefit for income taxes | 771 | (571 | ) | (3,712 | ) | ||||
| Net (loss) income before redeemable non-controlling interest | (25,607 | ) | (6,200 | ) | (19,830 | ) | |||
| Less: net (loss) attributable to redeemable non-controlling interest | (54 | ) | — | — | |||||
| Net (loss) income attributable to 3D Systems Corporation | $ | (25,553 | ) | $ | (6,200 | ) | $ | (19,830 | ) |
| Net income (loss) per share available to 3D Systems Corporation common stockholders | |||||||||
| Basic | $ | (0.20 | ) | $ | (0.05 | ) | $ | (0.16 | ) |
| Diluted | $ | (0.20 | ) | $ | (0.05 | ) | $ | (0.16 | ) |
^(1)^Amounts in table may not foot due to rounding
3D Systems Corporation Unaudited Consolidated Statements of Cash Flows
| Year Ended<br>December 31, | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| (in thousands) | 2022 | 2021 | 2020 | ||||||
| Cash flows from operating activities: | |||||||||
| Net (loss) income | $ | (122,949 | ) | $ | 322,052 | $ | (149,594 | ) | |
| Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities: | |||||||||
| Depreciation, amortization and accretion of debt discount | 38,686 | 34,623 | 44,595 | ||||||
| Stock-based compensation | 42,415 | 55,153 | 17,725 | ||||||
| Loss on short-term investments | 3,146 | — | — | ||||||
| Non-cash operating lease expense | 6,296 | — | — | ||||||
| Provision for inventory obsolescence and revaluation | (356 | ) | (2,909 | ) | 12,373 | ||||
| Loss on hedge accounting de-designation and termination | — | 721 | 1,235 | ||||||
| Provision for bad debts | 562 | 232 | 457 | ||||||
| Loss (gain) on the disposition of businesses, property, equipment and other assets | 104 | (350,846 | ) | 5,274 | |||||
| Benefit for deferred income taxes and reserve adjustments | (2,518 | ) | (11,679 | ) | (1,206 | ) | |||
| Asset impairment | 4,095 | 1,676 | 55,484 | ||||||
| Changes in operating accounts: | |||||||||
| Accounts receivable | 8,140 | (11,912 | ) | (6,052 | ) | ||||
| Inventories | (48,140 | ) | 7,866 | (9,901 | ) | ||||
| Prepaid expenses and other current assets | 8,223 | (8,106 | ) | (16,218 | ) | ||||
| Accounts payable | (2,695 | ) | 27,159 | (6,653 | ) | ||||
| Deferred revenue and customer deposits | (6,947 | ) | (3,325 | ) | 3,231 | ||||
| Accrued and other liabilities | 11,231 | (12,389 | ) | 28,286 | |||||
| All other operating activities | (7,688 | ) | (169 | ) | 843 | ||||
| Net cash (used in) provided by operating activities | (68,395 | ) | 48,147 | (20,121 | ) | ||||
| Cash flows from investing activities: | |||||||||
| Purchases of property and equipment | (22,499 | ) | (18,791 | ) | (13,643 | ) | |||
| Purchases of short-term investments | (384,388 | ) | — | — | |||||
| Sales and maturities of short-term investments | 200,314 | — | — | ||||||
| Proceeds from sale of assets and businesses, net of cash sold | 325 | 421,485 | 1,554 | ||||||
| Acquisitions and other investments, net of cash acquired | (103,647 | ) | (139,685 | ) | — | ||||
| Other investing activities | — | (2,454 | ) | 356 | |||||
| Net cash (used in) provided by investing activities | (309,895 | ) | 260,555 | (11,733 | ) | ||||
| Cash flows from financing activities: | |||||||||
| Proceeds from revolving credit facilities | — | — | 20,000 | ||||||
| Payments on revolving credit facilities | — | — | (20,000 | ) | |||||
| Proceeds from borrowings | — | 460,000 | — | ||||||
| Debt issuance costs | — | (13,466 | ) | — | |||||
| Repayment of borrowings/long-term debt | — | (21,392 | ) | (26,840 | ) | ||||
| Proceeds from issuance of common stock | — | — | 24,702 | ||||||
| Purchase of non-controlling interests | (2,300 | ) | (6,300 | ) | (12,500 | ) | |||
| Taxes paid related to net-share settlement of equity awards | (10,864 | ) | (12,619 | ) | (5,138 | ) | |||
| Other financing activities | (660 | ) | (423 | ) | 296 | ||||
| Net cash (used in) provided by financing activities | (13,824 | ) | 405,800 | (19,480 | ) | ||||
| Effect of exchange rate changes on cash, cash equivalents and restricted cash | (5,881 | ) | (9,243 | ) | 1,428 | ||||
| Net (decrease) increase in cash, cash equivalents and restricted cash | (397,995 | ) | 705,259 | (49,906 | ) | ||||
| Cash, cash equivalents and restricted cash at the beginning of the year ^a^ | 789,970 | 84,711 | 134,617 | ||||||
| Cash, cash equivalents and restricted cash at the end of the year ^a^ | $ | 391,975 | $ | 789,970 | $ | 84,711 |
^(a)^The amounts for cash and cash equivalents shown above include restricted cash of $114, $313 and $540 as of December 31, 2022, 2021 and 2020, respectively, which are included in prepaid expenses and other current assets. In addition, included in cash and cash equivalents above as of December 31, 2022 is $3,727 of restricted cash, which, is included in other non-current assets. Finally, included in cash and cash equivalents above as of December 31, 2020 is $9,161, which was included in current assets held for sale.
Appendix 3D Systems Corporation Unaudited Reconciliations of GAAP to Non-GAAP Measures Three Months and Year Ended December 31, 2022
| Three Months Ended December 31, | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| (in thousands, except per share amounts) | 2022 | 2022 | ||||||||||||||||
| GAAP | Amortization, stock-based compensation & other | Legal, acquisition and divestiture-related | Cost optimization plan | Impairment of cost-method investments | Non-GAAP | |||||||||||||
| Revenue | $ | 132,732 | $ | — | $ | — | $ | — | $ | — | $ | 132,732 | ||||||
| Gross Profit | 54,630 | $ | (398 | ) | $ | — | $ | — | $ | — | 54,231 | |||||||
| Gross Profit Margin | 41.2 | % | 40.9 | % | ||||||||||||||
| Operating expenses | 82,674 | $ | (14,596 | ) | $ | (3,553 | ) | $ | (377 | ) | $ | (3 | ) | 64,144 | ||||
| Operating income (loss) | (28,044 | ) | $ | 14,198 | $ | 3,553 | $ | 377 | $ | 3 | (9,912 | ) | ||||||
| Interest and other income (expense), net | 1,666 | $ | — | $ | (52 | ) | $ | — | $ | — | 1,614 | |||||||
| Net income (loss) | (25,553 | ) | $ | 14,188 | $ | 3,511 | $ | 377 | $ | 3 | (7,474 | ) | ||||||
| Net income (loss) EPS - basic | (0.20 | ) | 0.11 | 0.03 | — | — | (0.06 | ) | ||||||||||
| Net income (loss) EPS - diluted | $ | (0.20 | ) | $ | 0.11 | $ | 0.03 | $ | — | $ | — | $ | (0.06 | ) | ||||
| Weighted Average Shares - basic | 128,828 | 128.828 | ||||||||||||||||
| Weighted Average Shares - diluted | 128,828 | 128.828 | ||||||||||||||||
| ^(1)^Amounts in table may not foot due to rounding | ||||||||||||||||||
| Year Ended<br>December 31, | ||||||||||||||||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| (in thousands, except per share amounts) | 2022 | 2022 | ||||||||||||||||
| GAAP | Amortization, stock-based compensation & other | Legal, acquisition and divestiture-related | Cost optimization plan | Impairment of cost-method investments | Non-GAAP | |||||||||||||
| Revenue | $ | 538,031 | $ | — | $ | — | $ | — | $ | — | $ | 538,031 | ||||||
| Gross Profit | 214,233 | 14 | — | — | — | 214,247 | ||||||||||||
| Gross Profit Margin | 39.8 | % | 39.8 | % | ||||||||||||||
| Operating expenses | 331,252 | (49,995 | ) | (39,476 | ) | (638 | ) | (18 | ) | 241,124 | ||||||||
| Operating income (loss) | (117,019 | ) | 50,009 | 39,476 | 638 | 18 | (26,877 | ) | ||||||||||
| Interest and other income (expense), net | (3,790 | ) | — | 287 | — | 2,900 | (603 | ) | ||||||||||
| Net income (loss) | (122,711 | ) | 49,999 | 39,773 | 638 | 2,918 | (29,383 | ) | ||||||||||
| Net income EPS - basic | (0.96 | ) | 0.39 | 0.31 | — | 0.02 | (0.23 | ) | ||||||||||
| Net income EPS - diluted | $ | (0.96 | ) | $ | 0.39 | $ | 0.31 | $ | — | $ | 0.02 | $ | (0.23 | ) | ||||
| Weighted Average Shares - basic | 127,818 | 127,818 | ||||||||||||||||
| Weighted Average Shares - diluted | 127,818 | 127,818 | ||||||||||||||||
| ^(1)^Amounts in table may not foot due to rounding |
3D Systems Corporation Unaudited Reconciliations of GAAP to Non-GAAP Measures Three Months and Year Ended December 31, 2021
| Three Months Ended December 31, | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| (in thousands, except per share amounts) | 2021 | 2021 | |||||||||||||||||||||
| GAAP | Amortization, stock-based compensation & other | Legal, acquisition and divestiture-related^(1)^ | Cost optimization plan | Product end of life adjustment | Divestitures | Non-GAAP | |||||||||||||||||
| Revenue | $ | 150,870 | $ | — | $ | — | $ | — | $ | — | $ | — | $ | 150,870 | |||||||||
| Gross Profit | 66,218 | 200 | — | — | 200 | — | 66,620 | ||||||||||||||||
| Gross Profit Margin | 43.9 | % | 44.1 | % | |||||||||||||||||||
| Operating expenses | 70,060 | (13,169 | ) | (1,136 | ) | (1,494 | ) | — | — | 54,261 | |||||||||||||
| Operating income (loss) | (3,840 | ) | 13,369 | 1,136 | 1,494 | 200 | — | 12,359 | |||||||||||||||
| Interest and other income (expense), net | (1,787 | ) | — | 1,098 | — | — | — | (689 | ) | ||||||||||||||
| Net income (loss) | (6,200 | ) | 13,369 | 2,707 | 1,494 | 200 | — | 11,570 | |||||||||||||||
| Net income (loss) EPS - basic | (0.05 | ) | 0.11 | 0.02 | 0.01 | — | — | 0.09 | |||||||||||||||
| Net income (loss) EPS - diluted | $ | (0.05 | ) | $ | 0.10 | $ | 0.02 | $ | 0.01 | $ | — | $ | — | $ | 0.09 | ||||||||
| Weighted Average Shares - basic | 124,874 | 124,874 | |||||||||||||||||||||
| Weighted Average Shares - diluted | 127,884 | 127,884 | |||||||||||||||||||||
| ^(1)^Amounts in table may not foot due to rounding | |||||||||||||||||||||||
| Year Ended December 31, | |||||||||||||||||||||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| (in thousands, except per share amounts) | 2021 | 2021 | |||||||||||||||||||||
| GAAP | Amortization, stock-based compensation & other | Legal, acquisition and divestiture-related ^(1)^ | Cost optimization plan | Impairment of cost-method investments | Product end of life adjustment | Divestitures | Non-GAAP | ||||||||||||||||
| Revenue | $ | 615,639 | $ | — | $ | — | $ | — | $ | — | $ | — | $ | (71,672 | ) | $ | 543,967 | ||||||
| Gross Profit | 263,778 | 500 | — | — | 200 | (33,499 | ) | 230,979 | |||||||||||||||
| Gross Profit Margin | 42.8 | % | 42.5 | % | |||||||||||||||||||
| Operating expenses | 296,847 | (64,366 | ) | (16,284 | ) | (1,494 | ) | — | — | (17,253 | ) | 197,450 | |||||||||||
| Operating income (loss) | (33,069 | ) | 64,866 | 16,284 | 1,494 | — | 200 | (16,246 | ) | 33,529 | |||||||||||||
| Interest and other income (expense), net | 352,609 | — | (353,809 | ) | — | (43 | ) | — | 1,100 | (143 | ) | ||||||||||||
| Net income (loss) | 322,052 | 64,866 | (331,950 | ) | 1,494 | (43 | ) | 200 | (15,146 | ) | 41,473 | ||||||||||||
| Net (loss) EPS - basic | 2.62 | 0.53 | (2.70 | ) | 0.01 | — | — | (0.12 | ) | 0.34 | |||||||||||||
| Net (loss) EPS - diluted | $ | 2.55 | $ | 0.51 | $ | (2.63 | ) | $ | 0.01 | $ | — | $ | — | $ | (0.12 | ) | $ | 0.33 | |||||
| Weighted Average Shares - basic | 122,867 | 122,867 | |||||||||||||||||||||
| Weighted Average Shares - diluted | 126,334 | 126,334 | |||||||||||||||||||||
| ^(1)^Amounts in table may not foot due to rounding |
3D Systems Corporation Unaudited Non-GAAP Operating Income to Adjusted EBITDA Reconciliation Three Months and Year Ended December 31, 2022 and 2021
| Three Months Ended December 31,^(1)^ | Year Ended December 31,^(1)^ | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| (in thousands) | 2022 | 2021 | 2022 | 2021 | ||||||||
| Revenue | $ | 132,732 | $ | 150,870 | $ | 538,031 | $ | 543,967 | ||||
| Non-GAAP Operating Income | (9,912 | ) | 12,359 | (26,877 | ) | 33,529 | ||||||
| Depreciation | 5,104 | 5,570 | 21,096 | 22,622 | ||||||||
| Adjusted EBITDA | $ | (4,808 | ) | $ | 17,929 | $ | (5,781 | ) | $ | 56,151 | ||
| Adjusted EBITDA Margin | (3.6 | )% | 11.9 | % | (1.1)% | 10.3 | % | |||||
| ^(1)^Amounts in table may not foot due to rounding |
3D Systems Corporation Unaudited Reconciliation of Prior Years Revenue Excluding Divestitures (Non-GAAP) 2021 by Quarter
| 2021 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Three Months Ended | ||||||||||
| (in thousands) | March 31 | June 30 | September 30 | December 31 | Total | |||||
| Revenue | ||||||||||
| Healthcare | $ | 72,521 | $ | 82,826 | $ | 76,365 | $ | 74,472 | $ | 306,184 |
| Industrial | 73,595 | 79,731 | 79,731 | 76,398 | 309,455 | |||||
| Total Revenue | $ | 146,116 | $ | 162,557 | $ | 156,096 | $ | 150,870 | $ | 615,639 |
| Revenue From Divestitures: | ||||||||||
| Healthcare | $ | 11,008 | $ | 13,135 | $ | 7,652 | $ | — | $ | 31,795 |
| Industrial | 14,195 | 13,931 | 11,751 | — | 39,877 | |||||
| Total Revenue | $ | 25,203 | $ | 27,066 | $ | 19,403 | $ | — | $ | 71,672 |
| Total Revenue (Excl. Divest.): | ||||||||||
| Healthcare | $ | 61,513 | $ | 69,691 | $ | 68,713 | $ | 74,472 | $ | 274,389 |
| Industrial | 59,400 | 65,800 | 67,980 | 76,398 | 269,578 | |||||
| Total Revenue (Excl. Divest.): | $ | 120,913 | $ | 135,491 | $ | 136,693 | $ | 150,870 | $ | 543,967 |
| ^(1)^Amounts in table may not foot due to rounding |
3D Systems Corporation Unaudited Reconciliation of Revenue to Non-GAAP Revenue ^(1)^ Three Months and Year Ended December 31,
Table 4
| Three Months Ended December 31, 2022 | Three Months Ended December 31, 2021 | % Change | Constant Currency ^(2)^ | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| (in thousands) | FX Effect ^(3)^ | B(W)% | ||||||||||
| Revenue, as reported | ||||||||||||
| Healthcare | $ | 60,694 | $ | 74,472 | (18.5 | )% | ||||||
| Industrial | 72,038 | 76,398 | (5.7 | )% | ||||||||
| Total Revenue, as reported | $ | 132,732 | $ | 150,870 | (12.0 | )% | ||||||
| Revenue From Divestitures: | ||||||||||||
| Healthcare | $ | — | $ | — | ||||||||
| Industrial | — | — | ||||||||||
| Total Revenue | $ | — | $ | — | ||||||||
| Total Revenue (Excl. Divest. and FX Effect): | ||||||||||||
| Healthcare | $ | 60,694 | $ | 74,472 | (18.5 | )% | $ | (1,432 | ) | (16.6 | )% | |
| Industrial | 72,038 | 76,398 | (5.7 | )% | (5,168 | ) | 1.1 | % | ||||
| Total Revenue (Excl. Divest. and FX Effect): | $ | 132,732 | $ | 150,870 | (12.0 | )% | $ | (6,600 | ) | (7.6 | )% | |
| Year Ended December 31, 2022 | Year Ended December 31, 2021 | % Change | Constant Currency ^(2)^ | |||||||||
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| (in thousands) | FX Effect ^(3)^ | B(W)% | ||||||||||
| Revenue, as reported | ||||||||||||
| Healthcare | $ | 260,988 | $ | 306,184 | (14.8 | )% | ||||||
| Industrial | 277,043 | 309,455 | (10.5 | )% | ||||||||
| Total Revenue, as reported | $ | 538,031 | $ | 615,639 | (12.6 | )% | ||||||
| Revenue From Divestitures: | ||||||||||||
| Healthcare | $ | — | $ | 31,795 | ||||||||
| Industrial | 39,877 | |||||||||||
| Total Revenue | $ | — | $ | 71,672 | ||||||||
| Total Revenue (Excl. Divest. and FX Effect): | ||||||||||||
| Healthcare | $ | 260,988 | $ | 274,389 | (4.9 | )% | $ | (5,564 | ) | (2.9 | )% | |
| Industrial | 277,043 | 269,578 | 2.8 | % | (18,567 | ) | 9.7 | % | ||||
| Total Revenue (Excl. Divest. and FX Effect): | $ | 538,031 | $ | 543,967 | (1.1 | )% | $ | (24,131 | ) | 3.3 | % |
^(1)^Amounts in table may not foot due to rounding and percent changes have been calculated based upon rounded amounts ^(2)^ To assist in the analysis of the company’s revenue trends, the company estimated the impact of foreign exchange on year over year revenue growth by recasting revenue, excluding divestitures, for the three months and year ended December 31, 2022 by applying the foreign exchange rates used to translate 2021 non-US functional currency revenue to 2022 non-US functional currency revenue. ^(3)^ FX effect is the estimated impact on “as reported” net revenue due to changes in foreign currency exchange rates
EdgarFiling
EXHIBIT 99.2
Fourth Quarter 202 2 Financial Results March 1 , 202 3
2 Welcome and Participants Dr. Jeffrey Graves President & Chief Executive Officer Michael Turner Executive Vice President & Chief Financial Officer Andrew Johnson Executive Vice President & Chief Legal Officer Russell Johnson Vice President, Treasury & Investor Relations To participate via phone, please dial: 1 - 201 - 689 - 8345
Certain statements made in this presentation that are not statements of historical or current facts are forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 . Forward - looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to be materially different from historical results or from any future results or projections expressed or implied by such forward - looking statements . In many cases, forward looking statements can be identified by terms such as “believes,” “belief,” “expects,” “may,” “will,” “estimates,” “intends,” “anticipates” or “plans” or the negative of these terms or other comparable terminology . Forward - looking statements are based upon management’s beliefs, assumptions and current expectations and may include comments as to the company’s beliefs and expectations as to future events and trends affecting its business and are necessarily subject to uncertainties, many of which are outside the control of the company . The factors described under the headings “Forward - Looking Statements” and “Risk Factors” in the company’s periodic filings with the Securities and Exchange Commission, as well as other factors, could cause actual results to differ materially from those reflected or predicted in forward - looking statements . Although management believes that the expectations reflected in the forward - looking statements are reasonable, forward - looking statements are not, and should not be relied upon as a guarantee of future performance or results, nor will they necessarily prove to be accurate indications of the times at which such performance or results will be achieved . The forward - looking statements included are made only as the date of the statement . 3 D Systems undertakes no obligation to update or revise any forward - looking statements made by management or on its behalf, whether as a result of future developments, subsequent events or circumstances or otherwise, except as required by law Further, we encourage you to review “Risk Factors” in Part 1 of our Annual Report on Form 10 - K and Part II of our Quarterly Reports on Form 10 - Q filed with the SEC as well as other information about us in our filings with the SEC . These are available at www . SEC . gov . 3 Forward Looking Statements
Dr. Jeffrey Graves President & Chief Executive Officer 4
5 2022 Highlights • Challenging 2022 business environment • Macroeconomic and geopolitical headwinds • Softer dental market demand due to inflationary pressure on elective procedures • Pivoted in second half of year to finish near revised guidance • Efficiency gains from manufacturing in - sourcing • 2022 was year of strategic investment • Platform refreshes • Technology acquisitions • Regenerative medicine • Business well positioned for continued growth
New Hardware Platforms Driving Growth 6 • April 2022 – 3D Systems launches new SLA 750 • Feb 2023 – BWT Alpine F1 acquires four SLA 750s SLA 750 & SLA 750 Dual MJP 2500W Plus • Feb 2023 – 3D Systems launches MJP 2500W Plus Next - generation printer for higher throughput, higher resolution jewelry wax casting patterns
Accelerating Innovation thru Acquired Technology 7 University Hospital Salzburg Salzburg, Austria - February 2023 1st clinical implantation of PEEK cranial device printed on a Kumovis printer
Organ development partnership since 2017 Acquired in 2021 to expand bioprinting capabilities 35+ Years of developing advanced 3D printing applications Human Organs Regenerative Tissue Program Drug Development 3D printed human lung scaffold x 2 Lobes x 5,000 kilometers of vasculature x 213 Million Alveoli x 44 Trillion Voxels Most Complex Object Ever 3D Printed Vascularized Breast Tissue Scaffold for Implantation & Cellularization Bioprinted “Organ - on - a - chip” can accurately replicate organ - specific drug response in pre - clinical drug trials h - VIOS 2 chip with perfused vasculature 3D Systems Bioprinting Leadership 3D Systems Proprietary and Confidential Investing in Regenerative Medicine
9 2023 Priorities x Harvest benefits of technology platform investments x Invest in regenerative medicine for future growth x Continue to optimize manufacturing footprint x Organization - wide focus on cost synergies & operational excellence x Break Even to Positive Adjusted EBITDA and FCF
Michael Turner Chief Financial Officer 10
11 Q4 & FY 2022 Revenue Summary * see Appendix for reconciliation of revenue adjusted for divestitures and revenue adjusted for divestitures and in constant cu rre ncy • Q4 2022 revenue - $132.7 million • 12.0% decrease vs. Q4 2021 • 7.6% decrease vs. Q4 2021 in constant currency • FY 2022 revenue - $538.0 million • 12.6% decrease vs. FY 2021 • 3.3% increase vs. FY 2021 excluding divestitures and in constant currency Full Year 2022 Fourth Quarter 2022 Balance of business is well - positioned with solid demand and growth trends » Divestiture Impact » Significant FX headwinds » Russia exit reduced FY 2022 results » Dental market softness significantly impacted Q4 and FY 2022 results
12 Revenue by Segment ($ millions except percentages) Healthcare Solutions Industrial Solutions Full Year $274.4 $261.0 FY 2021 FY 2022 $269.6 $277.0 FY 2021 FY 2022 - 4.9% +2.8% Healthcare down 2.9% Constant Currency Industrial up 9.7% Constant Currency Fourth Quarter $74.5 $60.7 Q4 2021 Q4 2022 $76.4 $72.0 Q4 2021 Q4 2022 Healthcare down 16.6% Constant Currency Industrial up 1.1% Constant Currency - 18.5% - 5.7% 1 1 Adjusted for 2021 divestitures * see Appendix for reconciliation of revenue adjusted for divestitures and revenue in constant currency
13 Gross Profit Margin (non - GAAP) 44% 40% 38% 40% 41% 30% 35% 40% 45% 50% Q4 2021 Q1 2022 Q2 2022 Q3 2022 Q4 2022 FY 2022 vs. FY 2021 • FY 2022 GM% of 39.8% vs. FY 2021 42.5% • Impacted by divestitures, inflation, freight, and mix Q4 2022 vs. Q4 2021 • Q4 2022 GM% of 40.9% vs. Q4 2021 44.1% • Impacted by divestitures, inflation, freight, and mix Sequential Improvement Q2 Q4 • Focus on operational excellence, including continued benefits from Q3 2022 in - sourcing actions FY 2022 – 39.8%
14 Non - GAAP Operating Expenses (Non - GAAP excluding Divestitures - $ millions) $54.3 $57.8 $ 60.9 $ 58.3 $64.1 $0 $20 $40 $60 $80 Q4 2021 Q1 2022 Q2 2022 Q3 2022 Q4 2022 R&D SG&A See appendix for a reconciliation of non - GAAP operating expenses excluding divestitures . FY 2022 vs. FY 2021 • Non - GAAP opex of $241.1 million • 22.1% increase vs. FY 2021 • Acquisition opex • Increased R&D to enhance product portfolio and build regenerative medicine business • Investing in corporate infrastructure Q4 2022 vs. Q4 2021 • Non - GAAP opex of $64.1 million • 18.2% increase vs. Q4 2021 • Same drivers as Full Year FY 2022 – $241.1 million
15 $17.9 $1.9 $(2.6) $(0.3) $(4.8) 11.9% 1.4% - 1.9% - 0.2% - 3.8% -10% -5% 0% 5% 10% 15% 20% -$10 $0 $10 $20 $30 $40 $50 Q4 2021 Q1 2022 Q2 2022 Q3 2022 Q4 2022 Adj. EBITDA Adj. EBITDA Margin % Adj. EBITDA Margin % is defined as non - GAAP Operating Income excluding divestitures plus Depreciation divided by Revenue See appendix for a reconciliation of n on - GAAP Operating Income and Adjusted EBITDA. FY 2022 Adjusted EBITDA - ($5.8) million Q4 2022 Adjusted EBITDA – ($4.8) million • Impact from acquired businesses, most of which are in development stage or early commercialization • Investments in R&D and infrastructure Adjusted EBITDA & Adjusted EBITDA Margin % (Excluding Divestitures - $ millions)
16 Strong Balance Sheet • Ended the quarter with $568.7 million dollars of cash and short - term investments • We have sufficient cash to support organic growth, including in regenerative medicine • Invested $104.3 million in acquisitions and investments in FY 2022 • Current focus is on operational execution and integration of recent acquisitions
17 Financial Guidance Comments Full Year 2023 Guidance $545 – $575 million Revenue 40% – 42% Non - GAAP Gross Margin Break even or better Adjusted EBITDA Break even or better Free Cash Flow • 4% revenue growth (midpoint) • Mid - teens revenue growth ex - dental • Reflects » YoY decline in dental revenue » YoY increase in investment spending for regenerative medicine • Adjusted EBITDA and Free Cash Flow do not include restructuring costs • Free Cash Flow defined as: Adj. EBITDA less Δ WC less capex
18 Q&A Session 1 - 201 - 689 - 8345
19 Thank You Find out more at: www.3dsystems.com
©202 2 3D Systems, Inc. | All Rights Reserved. Appendix
21 Presentation of Information 3 D Systems reports its financial results in accordance with GAAP . Management also reviews and reports certain non - GAAP measures, including : non - GAAP revenue excluding divestitures and on a constant currency basis (sometimes referred to as excluding divestitures and FX effects), non - GAAP Gross profit, non - GAAP Gross profit margin, non - GAAP Operating expenses, non - GAAP Operating (loss)/income, non - GAAP Interest and other income/(expense), net, non - GAAP Net income (loss), non - GAAP Basic and Diluted Income (Loss) per Share, adjusted EBITDA and adjusted EBITDA Margin . These non - GAAP measures exclude certain special items that management does not view as part of 3 D Systems’ underlying results as they may be highly variable, may be unusual or infrequent, are difficult to predict and can distort underlying business trends and results . Management believes that the non - GAAP measures provide useful additional insight into underlying business trends and results and provide a more meaningful comparison of period - over - period results . Additionally, management uses the non - GAAP measures for planning, forecasting and evaluating business and financial performance, including allocating resources and evaluating results relative to employee compensation targets . 3 D Systems’ non - GAAP measures are not calculated in accordance with or as required by GAAP and may not be calculated the same as similarly titled measures used by other companies . These non - GAAP measures should thus be considered as supplemental in nature and not considered in isolation or as a substitute for the related financial information prepared in accordance with GAAP . A reconciliation of GAAP to non - GAAP financial measures is provided in the accompanying schedules in the Appendix . 3 D Systems does not provide forward - looking guidance for certain measures on a GAAP basis . The company is unable to provide a quantitative reconciliation of forward - looking non - GAAP gross profit margins and non - GAAP operating expenses to the most directly comparable forward - looking GAAP measures without unreasonable effort because certain items, including legal, acquisition expenses, stock - compensation expense, intangible amortization expense, restructuring expenses, and goodwill impairment, are difficult to predict and estimate . These items are inherently uncertain and depend on various factors, many of which are beyond the company’s control, and as such, any associated estimate and its impact on GAAP performance could vary materially .
Non - GAAP Reconciliation – Quarter Ended Dec. 31, 2021 (Unaudited) 22
Non - GAAP Reconciliation – Quarter Ended March 31, 2022 (Unaudited) 23
Non - GAAP Reconciliation – Quarter Ended June 30, 2022 (Unaudited) 24
Non - GAAP Reconciliation – Quarter Ended Sept. 30, 2022 (Unaudited) 25
Non - GAAP Reconciliation – Quarter Ended Dec. 31, 2022 (Unaudited) 26 (1)
Non - GAAP Operating Income to Adjusted EBITDA Reconciliation (in Millions, Unaudited) 27 (in millions) Q4-2021 Q1-2022 Q2-2022 Q3-2022 Q4-2022 Revenue - 2021 excludes revenue from divestiture 150.9$ 133.0$ 140.0$ 132.3$ 132.7$ Non-GAAP Operating (loss) income 12.3 (3.9) (7.6) (5.5) (9.9) Depreciation 5.6 5.8 5.0 5.2 5.1 Adjusted EBITDA 17.9$ 1.9$ (2.6)$ (0.3)$ (4.8)$ Adjusted EBITDA Margin 11.9% 1.4% (1.9)% (0.2)% (3.6)% (1) Amounts in table may not foot due to rounding and percent changes have been calculated based on rounded amounts.
Reconciliation of Revenue to Non - GAAP Revenue (1) (in Millions, Unaudited) 28
29 Reconciliation of Revenue to Non - GAAP Revenue (1) (in Millions, Unaudited)